Door Erik van Straten: In https://medicine.yale.edu/news-article/ysph-statement-regarding-hydroxychloroquine/ kun je lezen wat de werkgever en de FDA, al in juni 2020, vonden van de controversiële uitspraken van Professor Harvey Risch van Yale. Volgens bijvoorbeeld https://www.nature.com/articles/s41467-021-22446-z#change-history leidt hydroxychloroquine, als middel tegen Covid-19, tot hogere sterfte terwijl geen significante effecten van chloroquine zijn aangetoond, een stukje daaruit: This collaborative meta-analysis of 28 published or unpublished RCTs, including 10,319 patients, shows that treatment with HCQ was associated with increased mortality in COVID-19 patients, and there was no benefit from treatment with CQ. No differences were seen across subgroup analyses on patient setting, diagnosis confirmation, control type, publication status, or dose and the between-study heterogeneity was low. For CQ, the number of studies was too small to draw clear conclusions. This meta-analysis offers useful ...